Edition:
United States

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

5,830JPY
12:55am EDT
Change (% chg)

¥-10 (-0.17%)
Prev Close
¥5,840
Open
¥5,870
Day's High
¥5,920
Day's Low
¥5,820
Volume
562,900
Avg. Vol
878,666
52-wk High
¥6,080
52-wk Low
¥3,805

Latest Key Developments (Source: Significant Developments)

Chugai Pharmaceutical says waiver of claims in patent infringement lawsuit
Wednesday, 11 Apr 2018 02:47am EDT 

April 11 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it has decided to waive its claim in a patent infringement lawsuit against Nippon Kayaku Co Ltd <<<4272.T>>>.Says co filed a lawsuit to the Tokyo District Court on Aug. 17, 2017, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® Injection 60 and 150 (Herceptin® Injection) against Nippon Kayaku, the applicant for marketing approval of the biosimilar of Herceptin® Injection, citing such party's infringement of the application patents for the treatment of breast cancer owned by Genentech Inc.  Full Article

CHUGAI PHARMACEUTICAL says filing of patent infringement lawsuit and petition for provisional disposition order
Tuesday, 9 Jan 2018 01:29am EST 

Jan 9 (Reuters) - CHUGAI PHARMACEUTICAL Co Ltd <4519.T> ::Says it filed an application for assisting intervention with Zenyaku Kogyo Co Ltd in a lawsuit that Genentech Inc filed, wherein the plaintiff demands prohibition of sales etc. of Rituxan® Injection, against Sandoz K.K and Kyowa Hakko Kirin Co Ltd.Says the company has also filed an application for assisting intervention in a petition for provisional disposition order that has been filed with the lawsuit.  Full Article

Chiome Bioscience says termination of joint research contract
Monday, 18 Dec 2017 03:36am EST 

Dec 18 (Reuters) - Chiome Bioscience Inc <4583.T>:Says it announces termination of candidate antibody related joint research contract, which was signed between the co and CHUGAI PHARMACEUTICAL CO LTD <<<4519.T>>>, as the contract has expired on Dec. 31 .  Full Article

Chugai Pharmaceutical says change of chief executive officer
Tuesday, 12 Dec 2017 03:16am EST 

Dec 12 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it names current president and chief operating officer Tatsuro Kosaka as chief executive officer and president, effective late March 2018.  Full Article

R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I
Thursday, 16 Nov 2017 01:32am EST 

Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I.Says rating outlook stable -R&I.  Full Article

Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma
Tuesday, 14 Nov 2017 05:17am EST 

Nov 14 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it and TAIYO HOLDINGS CO LTD <<<4626.T>>> announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd., a wholly owned subsidiary of Taiyo Holdings.  Full Article

Chugai Pharmaceutical says lawsuit on patent infringement concerning Herceptin® injection and petition for provisional disposition order
Friday, 8 Sep 2017 02:26am EDT 

Sept 8 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says co has filed a lawsuit and a petition for provisional disposition order against Nippon Kayaku Co.,Ltd <<<4272.T>>>, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® injection 60 and 150 (Herceptin® injection) .Genentech Inc, a U.S.-based firm, is a patent holder and co is the exclusive licensee of Herceptin® injection .Says co and Genentech are the co-plaintiff of the lawsuit.  Full Article

Chugai Pharmaceutical aims to increase core oper profit to more than 100 bln Yen in year ending Dec. 2019 - Nikkei
Monday, 21 Aug 2017 01:28pm EDT 

Aug 21 (Reuters) - Nikkei::Chugai Pharmaceutical Co Ltd aims to increase its core operating profit to more than 100 billion yen ($920 million) in the year ending December 2019 - Nikkei.  Full Article

Chugai Pharmaceutical sells trusted beneficial rights of property
Friday, 12 May 2017 03:01am EDT 

May 12 (Reuters) - Chugai Pharmaceutical Co Ltd <1491.T>: :* Says it has sold the trusted beneficial rights of Tokyo-based property on May 12.  Full Article

Baxalta files lawsuit against Chugai Pharmaceutical and Genentech
Wednesday, 10 May 2017 11:03pm EDT 

May 11(Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Baxalta filed a lawsuit against the company and Genentech Inc., in U.S. on May 4.Says the lawsuit is mainly for a judgment for an injunction against infringement of patent right.  Full Article

BRIEF-Chugai Pharmaceutical To Invest 25 Bln Yen Into A Singapore Research Center By 2021-Nikkei‍​

* CHUGAI PHARMACEUTICAL LOOKS TO INVEST SOME 25 BILLION YEN INTO A SINGAPORE RESEARCH CENTER FOR BIOPHARMACEUTICALS BY 2021 - NIKKEI‍​ Source text :(s.nikkei.com/2CitZyn) Further company coverage: (bangalore.newsroom@thomsonreuters.com)